Website stats for Jakafi - jakafi.com
Important Safety Information Jakafi can cause serious side effects, including:Low blood counts: Jakafi (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. ...
jakafi.com was registered 1 decade 3 years ago. It has a alexa rank of #1,893,613 in the world. It is a domain having .com extension. It is estimated worth of $ 720.00 and have a daily income of around $ 3.00. As no active threats were reported recently, jakafi.com is SAFE to browse.
Traffic Report
| Daily Unique Visitors: | 463 |
| Daily Pageviews: | 926 |
Estimated Valuation
| Income Per Day: | $ 3.00 |
| Estimated Worth: | $ 720.00 |
Search Engine Indexes
| Google Indexed Pages: | Not Applicable |
| Yahoo Indexed Pages: | Not Applicable |
| Bing Indexed Pages: | 4 |
Search Engine Backlinks
| Google Backlinks: | Not Applicable |
| Bing Backlinks: | 1 |
| Alexa BackLinks: | Not Applicable |
Safety Information
| Google Safe Browsing: | No Risk Issues |
| Siteadvisor Rating: | Not Applicable |
| WOT Trustworthiness: |
 Very Poor
|
| WOT Privacy: |
Very Poor
|
| WOT Child Safety: |
Very Poor
|
Website Ranks & Scores
| Alexa Rank: | 1,893,613 |
| PageSpeed Score: | 89 ON 100 |
| Domain Authority: |
49 ON 100 
|
| Bounce Rate: | Not Applicable |
| Time On Site: | Not Applicable |
Web Server Information
Hosted IP Address:
34.196.241.156
Hosted Country:
US
Location Latitude:
39.0395Location Longitude:
-77.4918Search Engine Results For jakafi.com
Explore PV and MF Patients' Journey | The Purple Chair | Jakafi.com
Learn from the stories of polycythemia vera & myelofibrosis patients who ...
Financial Assistance and Support Options for Jakafi ® (ruxolitinib)
Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well ...
Jakafi: Uses, Dosage, Side Effects & Warnings - Drugs.com
Dec 16, 2021 ... Jakafi (ruxolitinib) is used to treat myelofibrosis, polycythemia vera, and graft versus host disease. Includes Jakafi side effects, ...
JAKAFI (Ruxolitinib) Label - Accessdata.fda.gov
Jakafi is a kinase inhibitor indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis,.
Jakafi: Hematocrit Control & Spleen Reduction in PV Patients
Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well ...
FAQs | Jakafi Patient Meetings
Each meeting will review information about Jakafi® (ruxolitinib) as a possible treatment option. They are not designed for those living with ...
Jakafi (Ruxolitinib): First FDA-Approved Medication for the ... - NCBI
Jakafi (Ruxolitinib): First FDA-Approved Medication for the Treatment of Patients with Polycythemia Vera · Similar to myelofibrosis and essential thrombocythemia ...
Definition of Jakafi - NCI Dictionary of Cancer Terms
It is also being studied in the treatment of some types of cancer. Jakafi blocks a protein called JAK, which may help keep abnormal blood cells or cancer cells ...
Jakafi (ruxolitinib) - Home - Facebook
About Jakafi® (ruxolitinib) What Is Jakafi? Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine ...
Jakafi Oncology Medication | Jakafi Resources - Avella Specialty ...
Jakafi is used to treat people with polycythemia vera who have already taken hydroxyurea, but it did not work well enough or they could not tolerate it.
Polycythemia Vera, Myelofibrosis, Acute & Chronic Graft-Versus ...
Learn about Jakafi® (ruxolitinib) – Used to treat adults with polycythemia vera who have taken hydroxyurea and it did not work well enough or they could not ...
Jakafi® - Oral Chemotherapy Education
Sep 28, 2018 ... Ruxolitinib (Jakafi®) is used to treat patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host...
Jul 15, 2021 ... Jakafi (ruxolitinib). Wilmington, DE: Incyte, 2020 (prescribing information) (https://www.jakafi.com/pdf/prescribing-information.pdf. opens ...
Jakafi® Provides Important Symptom Relief in Patients with ...
A Phase III trial finds that Jakafi® (ruxolitinib) more effectively controls symptoms than standard therapy for patients with polycythemia vera (PV).
Jakafi | Chemotherapy Drug Information | Chemocare.com
Jakafi™ is the trade for the generic drug ruxolitinib. In some cases, health care professionals may use the generic drug name ruxolitinib when referring to ...
Prior Authorization - Oncology – Jakafi® (ruxolitinib tablets) - Cigna
- https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_522_coveragepositioncriteria_oncology_jakafi_pa.pdf
Prior Authorization is recommended for prescription benefit coverage of Jakafi. All approvals are provided for the durations noted below. FDA Indication(s). 1.
Incyte Announces Results of Phase 3 RUXCOVID Study ... - BioSpace
Dec 14, 2020 ... Incyte Announces Results of Phase 3 RUXCOVID Study of Ruxolitinib (Jakafi®) as a Treatment for Patients with COVID-19 Associated Cytokine ...
Jakafi (ruxolitinib) 22132 - ConnectiCare
Jakafi (ruxolitinib). POLICY #. 22132. INDICATIONS. For treatment of patients with intermediate or high-risk myelofibrosis, including primary.
Jakafi Oral Tablet 20Mg Drug Medication Dosage Information - CVS
Jakafi Oral tablet 20mg Drug Medication Dosage information. Learn about the reported side effects, related class drugs, and how these medications will ...
Conditions that Jakafi oral Treats - WebMD
What Conditions does JAKAFI Treat? myelofibrosis; polycythemia vera; chronic graft-versus-host disease; graft-versus-host disease. Full Drug Information ...
Jakafi (ruxolitinib) dosing, indications, interactions, adverse...
Medscape - Indication dosing for Jakafi (ruxolitinib), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation ...
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
| H1 Headings: | Not Applicable | H2 Headings: | Not Applicable |
| H3 Headings: | Not Applicable | H4 Headings: | 3 |
| H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
| Total IFRAMEs: | 1 | Total Images: | 19 |
| Google Adsense: | Not Applicable | Google Analytics: | Not Applicable |
Two Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| healthcare provider | 13 | 1.003 % | No |
| to treat | 11 | 0.849 % | No |
| Jakafi is | 10 | 0.772 % | No |
| treat adults | 10 | 0.772 % | No |
| who have | 10 | 0.772 % | No |
| used to | 10 | 0.772 % | No |
| not work | 9 | 0.694 % | No |
| work well | 9 | 0.694 % | No |
| did not | 9 | 0.694 % | No |
| well enough | 9 | 0.694 % | No |
| your healthcare | 8 | 0.617 % | No |
| is used | 8 | 0.617 % | No |
| types of | 8 | 0.617 % | No |
| with Jakafi | 8 | 0.617 % | No |
| treatment with | 7 | 0.54 % | No |
| adults with | 6 | 0.463 % | No |
| side effects | 6 | 0.463 % | No |
| Discover how | 6 | 0.463 % | No |
| if you | 6 | 0.463 % | No |
| and they | 6 | 0.463 % | No |
Four Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| used to treat adults | 10 | 0.772 % | No |
| did not work well | 9 | 0.694 % | No |
| not work well enough | 9 | 0.694 % | No |
| Jakafi is used to | 8 | 0.617 % | No |
| is used to treat | 8 | 0.617 % | No |
| they did not work | 6 | 0.463 % | No |
| during treatment with Jakafi | 6 | 0.463 % | No |
| Discover how Jakafi is | 6 | 0.463 % | No |
| how Jakafi is used | 6 | 0.463 % | No |
| GVHD who have taken | 6 | 0.463 % | No |
| to treat adults with | 6 | 0.463 % | No |
| and they did not | 6 | 0.463 % | No |
| work well enough or | 5 | 0.386 % | No |
| years of age and | 4 | 0.309 % | No |
| 12 years of age | 4 | 0.309 % | No |
| age and older with | 4 | 0.309 % | No |
| children 12 years of | 4 | 0.309 % | No |
| of age and older | 4 | 0.309 % | No |
| adults and children 12 | 4 | 0.309 % | No |
| and children 12 years | 4 | 0.309 % | No |
HTTP Header Analysis
Status-Code: 200
Status: 200 OK
Server: nginx
Date: Sat, 18 Jun 2022 17:12:36 GMT
Content-Type: text/html; charset=UTF-8
Content-Length: 13016
Connection: keep-alive
Expires: Sun, 19 Nov 1978 05:00:00 GMT
Cache-Control: max-age=86400, public
Vary: Cookie
Link:
X-UA-Compatible: IE=edge
Content-language: en
X-Content-Type-Options: nosniff
X-Frame-Options: SAMEORIGIN
Last-Modified: Thu, 09 Jun 2022 12:22:49 GMT
ETag: "1654777369"
X-Generator: Drupal 8 (https://www.drupal.org)
X-Drupal-Cache: HIT
Content-Encoding: gzip
X-Request-ID: v-57c2cf46-eae7-11ec-8f07-9ffa17638cd0
X-AH-Environment: 01live
Age: 36117
Via: varnish
X-Cache: HIT
X-Cache-Hits: 480
Accept-Ranges: bytes
Domain Information
| Domain Registrar: |
CSC Corporate Domains, Inc.
|
|---|---|
| Registration Date: | 2011-06-10 1 decade 3 years 5 months ago |
| Last Modified: | 2022-06-06 2 years 5 months 2 weeks ago |
Domain Nameserver Information
| Host | IP Address | Country | |
|---|---|---|---|
| dns1.cscdns.net | |
156.154.130.100 | United States |
| dns2.cscdns.net | |
156.154.131.100 | United States |
DNS Record Analysis
| Host | Type | TTL | Extra |
|---|---|---|---|
| jakafi.com | A | 295 |
IP: 34.196.241.156 |
| jakafi.com | NS | 86400 |
Target: dns2.cscdns.net |
| jakafi.com | NS | 86400 |
Target: dns1.cscdns.net |
| jakafi.com | SOA | 300 |
MNAME: dns1.cscdns.net RNAME: hostmaster.cscdns.net Serial: 2018031629 Refresh: 3600 Retry: 300 Expire: 1814400 |
| jakafi.com | MX | 300 |
Priority: 10 Target: mx.jakafi.com.cust.b.hostedemail.com |
| jakafi.com | TXT | 86400 |
TXT: jakafi-prod.azurewebsites.net |
| jakafi.com | TXT | 86400 |
TXT: v=spf1 a mx include:spf.m.appature.com ~all |
Full WHOIS Lookup
Registry Domain ID:
1660893905_DOMAIN_COM-VRSN
Registrar WHOIS Server:
whois.corporatedomains.com
Registrar URL:
http://cscdbs.com
Updated Date: 2022-06-06T05:11:09Z
Creation
Date: 2011-06-10T13:46:02Z
Registry Expiry Date:
2023-06-10T13:46:02Z
Registrar: CSC Corporate Domains,
Inc.
Registrar IANA ID: 299
Registrar Abuse Contact Email:
[email protected]
Registrar Abuse Contact Phone:
8887802723
Domain Status: clientTransferProhibited
https://icann.org/epp#clientTransferProhibited
Domain Status:
serverDeleteProhibited
https://icann.org/epp#serverDeleteProhibited
Domain Status:
serverTransferProhibited
https://icann.org/epp#serverTransferProhibited
Domain Status:
serverUpdateProhibited
https://icann.org/epp#serverUpdateProhibited
Name Server:
DNS1.CSCDNS.NET
Name Server: DNS2.CSCDNS.NET
DNSSEC:
unsigned
URL of the ICANN Whois Inaccuracy Complaint Form:
https://www.icann.org/wicf/
>>> Last update of whois database:
2022-06-18T17:12:22Z
Similarly Ranked Websites
70E Solutions - The Electrical Safety Professionals
70E Solutions - The electric safety professionals. We offer many services such as glove testing, personal protective equipment sales, training, glove management and more.
1,893,655 
$ 720.00
KITCHENTOWN | Changing the Food System, One Startup at a Time
KitchenTown helps develop, commercialize and launch impact-driven food products. Commerical kitchen & Product Development.
1,893,684 $ 720.00